Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 4/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | CHUK | O15111 | 2/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700716 | 1.00 | PRKCI (0.44) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL31507871 | 0.79 | CHUK (0.51) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL12574854 | 0.79 | PRKCI (0.46) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL31514673 | 0.79 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL2147990 | 0.79 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL3124523 | 0.79 | PRKCI (0.46) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL17731714 | 0.79 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL760829 | 0.79 | CHUK (0.51) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL13666508 | 0.79 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A | |
| SCHEMBL15384626 | 0.79 | PRKCI (0.41) | PRKCIAXLADORA2AADORA1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103371-B | EGFR inhibitor and preparation method and application thereof | SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20250122202-A1 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | US | claimed |
| US-12227478-B2 | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | YUHAN CORPORATION (KR) | 2025-02-18 | — | — | US | claimed |
| EP-4403556-A1 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shandong New Time Pharmaceutical Co., Ltd. (CN) | 2024-07-24 | — | — | EP | claimed |
| CN-118103371-A | EGFR inhibitor and preparation method and application thereof | 山东新时代药业有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-113614069-B | Process for preparing (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine or a salt thereof and process for preparing tofacitinib using the same | 柳韩洋行 | 2024-05-28 | — | — | CN | claimed |
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | claimed |
| CN-115838370-A | EGFR inhibitor and preparation method and application thereof | 山东新时代药业有限公司 | 2023-03-24 | — | — | CN | claimed |
| WO-2023041071-A1 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 山东新时代药业有限公司 | 2023-03-23 | — | — | WO | claimed |
| CN-115181100-A | Sulfonamide micromolecule inhibitor with purine and pyrrolopyrimidine parent nucleus | 广西大学 | 2022-10-14 | — | — | CN | claimed |
| CN-113614069-A | Process for preparing (3R,4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine or a salt thereof and process for preparing tofacitinib using the same | 柳韩洋行 | 2021-11-05 | — | — | CN | claimed |
| WO-2020204647-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2020-10-08 | — | — | WO | claimed |
| CN-111072671-A | Preparation method of 5-bromo-2-chloro-7H-pyrrolo [2,3-d ] pyrimidine | 浙江理工大学 | 2020-04-28 | — | — | CN | claimed |
| CN-108864057-B | JAK and HDAC double-target-point inhibitor containing 4-aminopyrazole structure and preparation method and application thereof | 山东大学 | 2020-03-31 | — | — | CN | claimed |
| CN-108276414-B | A kind of preparation method of citric acid tropsch imatinib | 齐鲁天和惠世制药有限公司 | 2019-07-23 | — | — | CN | claimed |
| CN-107793417-A | Pyrrolo- [2,3 d] pyrimidines and its salt, and preparation method and pharmaceutical usage | 复旦大学 | 2018-03-13 | — | — | CN | claimed |
| WO-2016073771-A2 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2016-05-12 | — | — | WO | claimed |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | PFIZER, INC. (US) | 2011-11-24 | — | — | US | claimed |
| EP-1913000-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | Pfizer Products Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007012953-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | PFIZER PRODUCTS INC. (US) | 2007-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122202-A1 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | EGFR, NHERF1, AREG | PRKCI 220/4885AXL 990/4885ADORA2A 3735/4885 |
| US-12227478-B2 | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | JAK3, JAK1, JAK2 | PRKCI 219/4885AXL 1570/4885ADORA2A 4237/4885 |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | DPYD, CPS1, TYMS | PRKCI 1239/4885AXL 1463/4885ADORA2A 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.